1NCE Trains Software Innovators on Simplifying IoT Solutions
Introducing a new global certification program for software integrators, streamlining IoT development and accelerating innovation. 1NCE’s Partner Initiative expands its platform’s reach – now the largest global IoT network in the cloud - by training top integrators for cost-effective, seamless IoT solutions that work across all industries. Certified integrators increase customer success by accelerating project timelines by months and reducing implementation costs by up to 50 percent.
1NCE, one of the fastest-growing companies in the Internet of Things (IoT), announces the launch of its Certified Integrators Program (CIP). The program empowers external software developers to integrate seamlessly with 1NCE’s IoT platform, simplifying the development of connected solutions and enhancing customer success.
The program marks a new step for 1NCE’s Partner Initiative, which counts more than 80 companies supporting 1NCE and its 23,000 customers managing 30 million endpoints worldwide. By offering hands-on training and certification, 1NCE equips integrators with tools to deliver streamlined, cost-effective IoT implementations for businesses across industries.
A key aspect of 1NCE's strategy is its dedication to providing open access, enabling top software developers to collaboratively build connected products on the 1NCE platform. The CIP starts with a comprehensive education program for partners to become certified experts in 1NCE’s IoT platform, then continues with teaching tools that equip integrators with the skills needed to design and implement optimized solutions tailored to customer needs.
As of today, a dynamic group of 10 integrators from eight countries have successfully completed the certification process. These rising industry leaders are now better positioned to help customers develop connected products using the 1NCE platform – ensuring seamless integration, faster time-to-market and reduced costs.
These integrators – selected for their technical expertise and proven track record in IoT innovation – specialize in software development, device-to-cloud integration and advanced analytics.
- Centri Group Inc. (United States): Centri crafts state-of-the-art full-stack IoT solutions that turn ambitious ideas into market-ready products.
- Codico GmbH (Austria): CODICO is a name that stands for the Design-In distribution of high-quality active and passive electronic components and interconnect systems.
- Device Insight GmbH (Germany): Device Insight has been assisting companies in digitalization within the realms of IoT, Analytics & AI for more than 20 years.
- Emerge Soft (Poland): Emerge Soft specializes in development and integration of advanced IoT solutions, harnessing the power of connectivity.
- Fixme GmbH (Germany): FIXME specializes in rapid, sustainable engineering solutions.
- JSC SoftTeco LT (Lithuania): SoftTeco is an international IT company specializing in custom software development, mobile app solutions, and IT consulting.
- Meritech Co. Ltd. (Japan): Meritech's monoZ facilitates the transformation of physical products into smart and advanced systems swiftly and economically, empowering users with enhanced capabilities and operational efficiencies.
- Saijai Tech Co., Ltd. (Thailand): Saijai is a tech startup specializing in the development of IoT, IIoT, and Smart City solutions.
- Spring Computing Technologies Inc. (United States): SpringCT is a technology research and development company offering entire spectrum of product lifecycle services in IoT space.
- Suntech USA International (South Korea): Suntech | ST SUNLAB specializes in the design and manufacturing of both standard and custom hardware solutions for fleet management, vehicle security, driver behavior, fuel saving, asset & cargo tracking and insurance telematics.
Ivo Rook, Co-Chief Executive Officer at 1NCE: “When you set a new standard for building and managing connected products, you can’t do it alone. We’ve seen that our most successful customers work with partners. That’s why we’ve opened 1NCE’s doors to welcome the best minds in IoT.”
1NCE plans to expand the Certified Integrators Program, onboarding more partners globally and rolling out advanced training modules. This initiative underscores 1NCE’s commitment to fostering a collaborative IoT ecosystem where innovation thrives.
New customers can get started today at the 1NCE online shop. Support is available in 25 languages.
About 1NCE
1NCE is a company offering a software platform for connected products that delivers future-proof, hassle-free IoT in 173 countries and regions. The software platform enables customers to easily, securely and reliably collect device data and turn it into actionable intelligence. Learn more at www.1NCE.com and follow on Facebook, LinkedIn and Twitter/X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241212229693/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Announces Landmark GI Study Results From Over 4,600 Patients15.5.2025 04:12:00 CEST | Press release
Results at a glance:71.4% of MetaXplore™ reports from 4,616 patients identified actionable results41.9% tested positive for abnormal microbiome markers linked to gastrointestinal health9.9% tested positive for gastrointestinal markers, including inflammation, pancreatic insufficiency, or blood in stool19.6% of reports tested positive for multiple markers (microbiome and gastrointestinal)65% of patients reported health improvements following clinician-directed recommendations informed by MetaXplore Microba Life Sciences Limited (ASX: MAP) (“Microba” or the “Company”), a precision microbiome company, today announces preliminary results from the analysis of over 4,600 MetaXplore™ GI Plus test results, a comprehensive test for the assessment and management of lower gastrointestinal disorders, spanning symptoms including chronic pain, bloating, constipation, or diarrhea. This study demonstrates that MetaXplore can support clinicians to identify and address underlying gut issues that often g
Bloomstreet Enters into Strategic Partnership Agreement with Google Israel for Market Expansion in Japan15.5.2025 04:00:00 CEST | Press release
Optimizing Global Websites for the Japanese Visitors: Detailed UX/UI Adaptation, Comprehensive Japanese Localization, Extensive Localization and Cultural Relevance to Fit the Local Audience. Bloomstreet Inc. (Headquarters: Chuo-ku, Tokyo; President & CEO: Junichi Takayama; hereinafter “Bloomstreet”), a company that supports overseas enterprises entering the Japanese market, is pleased to announce a strategic partnership agreement with Google Israel Ltd. (Headquarters: Tel Aviv District; Country Manager: Barak Regev; hereinafter “Google Israel”). This partnership aims to support Israeli companies that operate globally with Google Ads and are seeking to expand into the Japanese market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250514387485/en/ How do Bloomstreet and Google Israel collaborate? The partnership between Bloomstreet and Google Israel is designed to support Israeli companies seeking to expand into the Japanese
Rubedo Life Sciences’ Drug Discovery Platform, ALEMBIC™, Helps Identify Senescent or “Zombie” Neurons in New Study Linking Neuropathic Pain and Aging Published in Peer-Reviewed Scientific Journal Nature Neuroscience15.5.2025 03:11:00 CEST | Press release
Study is the first demonstration of senescent neurons driving neuropathic pain1 Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™ identified senescent neurons as novel therapeutic targets2 Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on discovering and rapidly developing selective cellular rejuvenation medicines targeting aging cells, today announced that using open source codes integrated in the company’s broader propriety drug discovery platform, ALEMBIC™, helped to identify senescent neurons in a new study that found senescent neurons drive chronic pain with injury and age.1 Senescent cells, often called “zombie” cells, arise as the results of cellular stress and damage. These senescent cells do not die but undergo cellular changes, including secreting pro-inflammatory factors, thereby potentially contributing to inflammatory responses within the body.1 The study, led by Stanford University scientists, Vivianne Tawfik, MD, PhD, and
The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 114.5.2025 23:03:00 CEST | Press release
–Data Demonstrated Statistically Significant Improvements in Primary and Secondary Endpoints with Most Subjects Achieving Near Normal Ranges of Wakefulness and Clinically Meaningful Improvements Across the Broad Range of Symptoms Investigated–Oveporexton Found to be Generally Safe and Well Tolerated–Phase 3 Readout of Oveporexton Anticipated in 2025 Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) in people with narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to restore orexin signaling to address the underlying orexin deficiency that causes NT1. Results demonstrated significant improvement in objective and subjective measures of excessive daytime sleepiness (EDS), reductions in cataplexy events and clinically meaningful improvements in disease severity and quality of life across all doses tested compared to placebo thro
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation14.5.2025 22:05:00 CEST | Press release
Data across 31 abstracts illustrate BeiGene’s deep commitment to transforming treatment for B-cell malignanciesFour oral presentations highlight updated data from investigational BTK protein degrader BGB-16673 and BCL2 inhibitor sonrotoclax across a range of B-cell malignancies BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Ltd., today announced it will share data across a range of hematologic malignancies at the European Hematology Association (EHA) Congress in Milan, Italy, June 12–15. BeiGene has 31 abstracts accepted at EHA 2025, with four selected for oral presentations, featuring data from its best-in-class Bruton’s tyrosine kinase (BTK) inhibitor BRUKINSA® (zanubrutinib) and its investigational pipeline assets – a next-generation BCL2 inhibitor, sonrotoclax, and BTK protein degrader, BGB-16673. These data reflect BeiGene’s vision to redefine standards of care in hematology through next-generation scie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom